Clinical Trial Update: Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating soluble Beta-1,3/1,6-glucan (SBG) versus placebo for chronic diabetic foot ulcers has completed, assessing efficacy and safety outcomes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Diabetic Foot Ulcer

Drugs mentioned

• Soluble Beta-1,3/1,6-glucan (SBG) (beta-1,3/1,6-glucan)

Snippet

Sponsor: Biotec Pharmacon ASA | Conditions: Diabetes, Diabetic Ulcer | Phase 3 | Status: COMPLETED